Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis

Archives of Internal Medicine

Volumn 159, Issue 4, 1999, Pages 337-345

  Girolami, Bruno ^a,c   Bernardi, Enrico ^a   Prins, Martin H ^b   Ten Cate, Jan Wouter ^b   Hettiarachchi, Rohan ^b   Prandoni, Paolo ^a   Girolami, Antonio ^a   Büller, Harry R ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NAFTIDROFURYL; PENTOXIFYLLINE;

ADULT; BLOOD VISCOSITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOMES RESEARCH; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; TRAINING; WALKING;

CLINICAL TRIALS; EXERCISE THERAPY; HUMANS; INTERMITTENT CLAUDICATION; NAFRONYL; PENTOXIFYLLINE; SMOKING CESSATION; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0033593881     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.4.337     Document Type: Review

References (116)

1. Fontaine VR, Kim M, Kicny R. Die chirurgische Behandlung der peripheren Durchblutungsstörungen. Helv Chir Acta. 1954;5/6:499-533.
2. Drummond M, Davies L. Economic evaluation of drugs in peripheral vascular disease and stroke. J Cardiovasc Pharmacol. 1994;23(suppl 3): 4S-7S.
3. Rudofsky G, van Laak HH. Treatment costs of peripheral arterial occlusive disease in Germany: a comparison of costs and efficacy. J Cardiovasc Pharmacol. 1994;23(suppl 3):22S-25S.
4. Dormandy J, Mahir M, Acsády G, et al. Fate of the patient with chronic leg ischaemia. J Cardiovasc Surg (Torino). 1989;30:50-57.
5. Balkau B, Vray M, Eschwege E. Epidemiology of peripheral arterial disease. J Cardiovasc Pharmacol. 1994;23(suppl3):8S-16S.
6. Kannel WB, Skinner JJ, Schwartz MJ, Shurtleff D. Intermittent claudication: incidence in the Framingham Study. Circulation. 1970;41:875-883.
7. Verstraete M. Current therapy for intermittent claudication. Drugs. 1982;24:240-247.
8. Lowe GDO. Drugs in cerebral and peripheral arterial disease. BMJ. 1990;300:524-528.
9. Spitzer S, Bach R, Schieffer H. Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II: a review. Int Angiol. 1992;11:204-210.
10. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis. JAMA. 1995;274:975-980.
11. Ernst E. Peripheral vascular disease: benefits of exercise. Sports Med. 1991;12:149-151.
12. Tsang GMK, Green MA, Crow AJ, et al. Chronic muscle stimulation improves ischaemic muscle performance in patients with peripheral vascular disease. Eur J Vasc Surg. 1994;8:419-422.
13. Hughson WG, Mann JI, Tibbs DJ, Woods HF, Walton I. Intermittent claudication: factors determining outcome. BMJ. 1978;1:1377-1379.
14. Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. BMJ. 1978;1:1379-1381.
15. Quick CRG, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982;69(suppl):S24-S26.
16. Jonason T, Ringqvist I. Factors of prognostic importance for subsequent rest pain in patients with intermittent claudication. Acta Med Scand. 1985; 218:27-33.
17. Kannel WB, Shurtleff D. The Framingham Study: cigarettes and the development of intermittent claudication. Geriatrics. 1973;28:61-68.
18. Juergens J, Barker N, Hines E. Atherosclerosis obliterans: review of 520 cases with special reference to pathogenic and prognostic factors. Circulation. 1960;21:188-195.
19. Bevan EG, Waller PC, Ramsay LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs Aging. 1992;2:125-136.
20. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol. 1988; 26:569-576.
21. Kriessmann A. Peripheral arterial occlusive disease: conservative treatment of intermittent claudication. J Cardiovasc Pharmacol. 1990;16 (suppl 3):S72-S74.
22. Radack K, Wydersky RJ. Conservative management of intermittent claudication. Ann Intern Med. 1990;113:135-146.
23. Rao CR. Linear Statistical Inference and Its Applications. New York, NY: John Wiley & Sons Inc; 1973;389-391.
24. Ekroth R, Dahllöf AG, Gundevall B, Holm J, Schersten T. Physical training of patients with intermittent claudication: indications, methods, and results. Surgery. 1978;84:640-643.
25. Sorlie D, Myhre K. Effects of physical training in intermittent claudication. Scand J Clin Lab Invest. 1978;38:217-222.
26. Kiesewetter H, Jung F, Blume J, Bulling B, Gerhards M. Conservative drug therapy and walking exercise in stage IIb peripheral arterial occlusion disease. Klin Wochenschr. 1986;64: 1061-1069.
27. Carter SA, Hamel ER, Paterson JM, Snow CJ, Mymin D. Walking ability and ankle systolic pressures: observations in patients with intermittent claudication in a short-term walking exercise program. J Vasc Surg. 1989;10:642-649.
28. Andriessen MP, Barendsen GJ, Wouda AA, dePater L. The effect of six months intensive physical training on the circulation in the legs of patients with intermittent claudication. Vasa. 1989;18:56-62.
29. Williams LR, Ekers MA, Collins PS, Lee JF. Vascular rehabilitation: benefits of a structured exercise/risk modification program. J Vasc Surg. 1991;14:320-326.
30. Lepantalo M, Sundberg S, Gordin A. The effects of physical training and flunarizine on walking capacity in intermittent claudication. Scand J Rehabil Med. 1984;16:159-162.
31. Jonason T, Jonzon B, Ringqvist I, Öman-Rydberg A. Effect of physical training on different categories of patients with intermittent claudication. Acta Med Scand. 1979;206:253-258.
32. Clifford PC, Davies PW, Hayne JA, Baird RN. Intermittent claudication: is a supervised exercise class worth while? BMJ. 1980;280:1503-1505.
33. Jonason T, Ringqvist I. Effect of training on the post-exercise ankle blood pressure reaction in patients with intermittent claudication. Clin Physiol. 1987;7:63-69.
34. Hiatt WR, Nawaz D, Regensteiner JG, Hossack KF. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulm Rehabil. 1988;12:525-532.
35. Ruell PA, Imperial ES, Bonar FJ, Thursby PF, Gass GC. The effect of physical training on walking tolerance and venous lactate concentration. Eur J Appl Physiol. 1984;52:420-425.
36. Boyd CE, Bird PJ, Teates CD, Wellons HA, MacDougall MA, Wolfe LA. Pain free physical training in intermittent claudication. J Sports Med. 1984;24:112-122.
37. 1 and naftidrofuryl infusion therapy in patients with intermittent claudication: a controlled study. Vasa. 1989;28(suppl):26-30.
38. Andriessen MPHM, Barendsen GJ, Wouda AA, De Pater L. Changes of walking distance in patients with intermittent claudication during six months intensive physical training. Vasa. 1989; 18:63-68.
39. Holm J, Schersten T. Exercise training of patients with intermittent claudication. Scand J Rehabil Med. 1983;9(suppl):20-26.
40. Alpert JS, Larsen OE, Lassen NA. Exercise and intermittent claudication: blood flow in the calf muscle during walking studied by xenon-133 clearance method. Circulation. 1969;39:353-359.
41. Wisham LH, Abramson AS, Ebel A. Value of exercise in peripheral arterial disease. JAMA. 1953; 5:10-12.
42. Jonason T, Ringqvist I. Prediction of the effect of training on the walking tolerance in patients with intermittent claudication. Scand J Rehabil Med. 1987;19:47-50.
43. Feinberg RL, Gregory RT, Wheeler JR, et al. The ischemic window: a method for the objective quantitation of the training effect in exercise therapy for intermittent claudication. J Vasc Surg. 1992;16:244-250.
44. McAllister FF. The fate of patients with intermittent claudication managed nonoperatively. Am J Surg. 1976;132:593-595.
45. Myhre K, Sorlie DG. Physical activity and peripheral atherosclerosis. Scand J Soc Med Suppl. 1982;29:195-201.
46. Rosetzsky A, Struckmann J, Mathiesen FR. Minimal walking distance following exercise treatment in patients with arterial occlusive disease. Ann Chir Gynaecol. 1985;74:261-264.
47. Pancera P, Prior M, Zannoni M, Lucchese L, De Marchi S, Arosio E. Micro- and macrocirculatory, and biohumoral changes after a month of physical exercise in patients with intermittent claudication. Scand J Rehabil Med. 1995;27:73-76.
48. Skinner JS, Strandness DE Jr. Exercise and intermittent claudication: effect of physical training. Circulation 1967;36:23-29.
49. Hall JA, Barnard RJ. The effects of an intensive 26-day program of diet and exercise on patients with peripheral vascular disease. J Cardiac Rehabil. 1982;2:569-574.
50. Pritikin N, Kern J, Kaye SM. Diet and exercise as a total therapeutic regimen for the rehabilitation of patients with severe peripheral vascular disease. Arch Phys Med Rehabil. 1975;56:558.
51. Zetterqvist S. The effect of active training on the nutritive blood flow in exercising ischemic legs. Scand J Clin Lab Invest. 1970;25:101-111.
52. Skinner JS, Strandness DE. Exercise and intermittent claudication: effect of repetition and intensity of exercise. Circulation. 1967;36:15-22.
53. Blumchen G, Landry F, Kiefer H, Schlosser V. Hemodynamic response of claudicating extremities: evaluation of a long range exercise program. Cardiology. 1970;55:114-127.
54. Jonason T, Ringqvist I, Öman-Rydberg A. Home-training of patients with intermittent claudication. Scand J Rehabil Med. 1981;13:137-141.
55. Johnson EC, Voyles WF, Atterbom HA, Pathak D, Button ME, Greene ER. Effects of exercise training on common femoral artery blood flow in patients with intermittent claudication. Circulation. 1989;80(suppl III):III-59-III-72.
56. Perkins JMT, Collin J, Creasy TS, Fletcher EWL, Morris PJ. Exercise training versus angioplasty for stable claudication: long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg. 1996;11:409-413.
57. Lundgren F, Dahllöf AG, Schersten T, Bylund-Fellenius AC. Muscle enzyme adaption in patients with peripheral arterial insufficiency: spontaneous adaption, effect of different treatments and consequences on walking performance. Clin Sci. 1989;77:485-493.
58. Holm J, Dahllöf AG, Bjorntorp P, Schersten T. Enzyme studies in muscles of patients with intermittent claudication: effect of training. Scand J Clin Lab Invest. 1973;128(suppl):201-205.
59. Larsen OA, Lassen NA. Effect of daily muscular exercise in patients with intermittent claudication. Scand J Clin Lab Invest 1966;99(suppl):168-171.
60. Cronenwett JL, Warner KG, Zelenock GB, et al. Intermittent claudication: current results of non-operative management. Arch Surg. 1984;119: 430-436.
61. Regensteiner JG, Steiner JF, Hiatt WR. Exercise improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996;23: 104-115.
62. Lundgren F, Dahllöf AG, Lundholm K, Schersten T, Volkmann R. Intermittent claudication: surgical reconstruction or physical training? a prospective randomized trial of treatment efficiency. Ann Surg. 1989;209:346-355.
63. Mannarino E, Pasqualini L, Innocente S, Scricciolo V, Rignanese A, Ciuffetti G. Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: alone or combined? Angiology. 1991;42:513-521.
64. Dahllöf AG, Bjorntorp P, Holm J, Schersten T. Metabolic activity of skeletal muscle in patients with peripheral arterial insufficiency: effect of physical training. Eur J Clin Invest. 1974;4:9-15.
65. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Circulation. 1994;90:1866-1874.
66. Larsen OA, Lassen NA. Effect of daily muscular exercise in patients with intermittent claudication. Lancet. 1966;2:1093-1096.
67. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation. 1990;81:602-609.
68. Dahllöf AG, Holm J, Schersten T, Sivertsson R. Peripheral arterial insufficiency: effect of physical training on walking tolerance, calf blood flow, and blood flow resistance. Scand J Rehabil Med. 1976;8:19-26.
69. Mannarino E, Pasqualini L, Menna M, Maragoni G, Orlandi U. Effects of physical training on peripheral vascular disease: a controlled study. Angiology. 1989;40:5-10.
70. Ernst EEW, Matrai A. Intermittent claudication, exercise, and blood rheology. Circulation. 1987; 76:1110-1114.
71. Ericsson B, Haeger K, Lindell SE. Effect of physical training on intermittent claudication. Angiology. 1970;21:188-192.
72. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Acta Med Scand. 1987;221:253-260.
73. Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg. 1996; 11:402-408.
74. Vasli LR, Foss OP. Serum thiocyanate, smoking habits and smoking cessation trial in patients with peripheral atherosclerosis. Scand J Clin Lab Invest. 1987;47:399-403.
75. Porter JM, Baur GM. Pharmacologic treatment of intermittent claudication. Surgery. 1982;92: 966-971.
76. Reich T, Gillings D. Effects of pentoxifylline on severe intermittent claudication. Angiology. 1987; 38:651-656.
77. Reich T, Cutler BC, Lee BY, et al. Pentoxifylline in the treatment of intermittent claudication of the lower limbs. Angiology. 1984;35:389-395.
78. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982;104: 66-72.
79. Gillings D, Koch G, Reich T, Stager WJ. Another look at the pentoxifylline efficacy data for intermittent claudication. J Clin Pharmacol. 1987; 27:601-609.
80. Roeren T, LeVeen RF, Nugent L. Photoplethys-mographic documentation of improved microcirculation after pentoxifylline therapy. Angiology. 1988;39:929-933.
81. AbuRahma AF, Woodruff BA. Effects and limitations of pentoxifylline therapy in various stages of peripheral vascular disease of the lower extremity. Am J Surg. 1990;160:266-270.
82. Poggesi L, Scarti L, Boddi M, Masotti G, Serneri GG. Pentoxifylline treatment in patients with occlusive peripheral arterial disease: circulatory changes and effects on prostaglandin synthesis. Angiology. 1985;36:628-637.
83. Pignoli P, Ciccolo F, Villa V, Longo T. Comparative evaluation of buflomedil and pentoxiphylline in patients with peripheral arterial occlusive disease. Curr Ther Res. 1985;37:596-606.
84. Chacon-Quevedo A, Eguaras MG, Calleja F, et al. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs. Angiology. 1994;45:647-653.
85. Perhoniemi V, Salmenkivi K, Sundberg S, Johnsson R, Gordin A. Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication. Angiology. 1984;35:366-372.
86. Feine-Haake G. Assessment of the therapeutic efficacy of pentoxifylline (Trental): a double-blind trial in geriatric patients with vascular disorder. Pharmatherapeutica. 1983;3(suppl 1):46-51.
87. Accetto B. Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of a double-blind study versus vasodilator-nylidrin. Am Heart J. 1982;103: 864-869.
88. Trübestein G, Trübestein R, Duong QD. Comparative evaluation of the effectiveness of buflomedil and pentoxiphylline in patients with arterial occlusive disease. Angiology. 1981;32: 705-709.
89. Mashiah A, Patel P, Schraibman IG, Charlesworth D. Drug therapy in intermittent claudication: an objective assessment of the effects of three drugs in patients with intermittent claudication. Br J Surg. 1978;65:342-345.
90. Deutschinoff A, Grozdinsky L. Rheological and anticoagulant therapy of patients with chronic peripheral occlusive arterial disease (COAD). Angiology. 1987;38:351-358.
91. Dettori AG, Pini M, Moratti A, et al. Acenocoumarol and pentoxifylline in intermittent claudication: a controlled clinical study. Angiology. 1989;40:237-248.
92. Ernst E, Kollar L, Resch KL. Does pentoxifylline prolong the walking distance in exercised claudicants? a placebo-controlled double-blind trial. Angiology. 1992;43:121-125.
93. Lindgärde F, Jelnes R, Bjorkman H, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation. 1989;80:1549-1556.
94. Donaldson DR, Hall TJ, Kester RC, Ramsden CW, Wiggins PA. Does oxpentifylline (Trental) have a place in the treatment of intermittent ciaudication? Curr Med Res Opin. 1984;9:35-40.
95. Di Perri T, Guerrini M. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology. 1983;34:40-45.
96. Reilly DT, Quinton DN, Barrie WW. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. N Z Med J. 1987;100:445-447.
97. Gallus AS, Gleadow F, Dupont P, et al. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Aust N Z J Med. 1985;15:402-409.
98. Bollinger A, Frei CH. Double-blind trial of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica. 1977;1:557-561.
99. Volker D. Treatment of artheriopathies with pentoxifylline (Trental 400): results of a double-blind study. Pharmatherapeutica. 1983;3(suppl 1):136-142.
100. Tonak J, Knecht H, Groitl H. Treatment of circulatory disturbances with pentoxifylline: double-blind study with Trental. Pharmatherapeutica. 1983;3(suppl 1):126-135.
101. Rudofsky G, Haussler KF, Künkel HP, et al. Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline. Angiology. 1989;40:639-649.
102. 1 or intravenous pentoxifylline during training. Circulation. 1994;90:818-822.
103. Waters KJ, Craxford AD, Chamberlain J. The effect of naftidrofuryl (Praxilene) on intermittent claudication. Br J Surg. 1980;67:349-351.
104. Ruckley CV, Callam MJ, Ferrington CM, Prescott RJ. Naftidrofuryl for intermittent claudication: a double-blind controlled trial. BMJ. 1978; 1:620.
105. Rosas G, Cerdeyra C, Lucas MA, Parano JR, Villa JJ. Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication. Angiology. 1981;32:291-297.
106. Karnik R, Valentin A, Stöllberger C, Slany J. Effects of naftidrofuryl in patients with intermittent claudication. Angiology. 1988;39:234-240.
107. Adhoute G, Bacourt F, Barral M, et al. Naftidrofuryl in chronic arterial disease: results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology. 1986;37: 160-167.
108. Trübestein G, Böhme H, Heidrich H, et al. Naftidrofuryl in chronic arterial occlusive disease: results of a controlled multicenter study. Angiology. 1984;35:701-708.
109. Adhoute G, Andreassian H, Boccalon M, et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotoninergic antagonist naftidrofuryl: results after six months of a controlled multicenter study. J Cardiovasc Pharmacol. 1990;16(suppl 3):S75-S80.
110. Moody AP, Al-Khaffaf HS, Lehert P, Harris PL, Charlesworth D. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol. 1994;23(suppl 3):S44-S47.
111. Clyne CAC, Galland RB, Fox MJ, Gustave R, Jantet GH, Jamieson CW. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication. Br J Surg. 1980;67: 347-348.
112. Patterson RB, Pinto B, Marcus B, Colucci A, Braun T, Roberts M. Value of a supervised exercise program for the therapy of arterial claudication. J Vasc Surg. 1997;25:312-319.
113. Regensteiner JG, Meyer TJ, Krupski WC, Cranford LS, Hiatt WR. Hospital-vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology. 1997;48: 291-300.
114. Girolami B, Bernardi E, Koelemay M, Prandoni P, Girolami A, Prins MH. Pharmacological treatment of peripheral arterial occlusive disease (Fontaine's stage II): a meta-analysis of randomised clinical trials [abstract]. Thromb Haemost. 1995; 6:1386.
115. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ. 1996;155:1053-1059.
116. Grégorie G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol. 1995;48:159-163.